Litigation Details for Novartis Pharmaceuticals Corporation v. Handa Neuroscience, LLC (D. Del. 2021)

Novartis Pharmaceuticals Corporation v. Handa Neuroscience, LLC (D. Del. 2021)

Docket		Date Filed	2021-05-04
Court	District Court, D. Delaware	Date Terminated
Cause	35:1 Patent Infringement	Assigned To
Jury Demand	None	Referred To
Patents	10,543,179; 9,187,405
Link to Docket	External link to docket

Details for Novartis Pharmaceuticals Corporation v. Handa Neuroscience, LLC (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2021-05-04	4	Patent/Trademark Report to Commissioner of Patents	Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,187,405 ;10,543,179. (apk) (Entered… 4 May 2021 1:21-cv-00645 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2022-02-28	47	Opinion - Memorandum Opinion	and 10,543,179 (the" ' 179 patent"). (Id. ,r 1) Two days later, Plaintiff …enforce two patents covering GILENYA® : U. S. Patent Nos. 9,187,405 (the '"405 patent") and… In a patent infringement action, venue is governed solely and exclusively by the patent venue statute… of Novartis litigating these patents; especially the ' 405 patent in this district for years successfully…District of California, asserting the same two patents against the same four Defendants, purportedly	External link to document
2022-05-17	75	Notice of Service	Invalidity Contentions Regarding U.S. Patent Nos. 9,187,405 and 10,543,179 filed by Novartis Pharmaceuticals… 4 May 2021 1:21-cv-00645 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document